Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2016

01-12-2016 | Original Article

Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH

Authors: Kei Taniguchi, Yoshifuru Tamura, Takanori Kumagai, Shigeru Shibata, Shunya Uchida

Published in: Clinical and Experimental Nephrology | Issue 6/2016

Login to get access

Abstract

Background

Hypouricemia is pathognomonic in syndrome of inappropriate secretion of antidiuretic hormone (SIADH) but the underlying mechanism remains unclear. Based on the previous studies, we hypothesized that V1a receptor may play a principal role in inducing hypouricemia in SIADH and examined uric acid metabolism using a rat model.

Methods

Terlipressin (25 ng/h), a selective V1a agonist, was subcutaneously infused to 7-week-old male Wistar rats (n = 9). Control rats were infused with normal saline (n = 9). The rats were sacrificed to obtain kidney tissues 3 days after treatment. In addition to electrolyte metabolism, changes in expressions of the urate transporters including URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2 and NPT1 (SLC17A1) were examined by western blotting and immunohistochemistry.

Results

In the terlipressin-treated rats, serum uric acid (UA) significantly decreased and the excretion of urinary UA significantly increased, resulting in marked increase in fractional excretion of UA. Although no change in the expression of URAT1, GLUT9 expression significantly decreased whereas the expressions of ABCG2 and NPT1 significantly increased in the terlipressin group. The results of immunohistochemistry corroborated with those of the western blotting. Aquaporin 2 expression did not change in the medulla, suggesting the independence of V2 receptor stimulation.

Conclusion

Stimulation of V1a receptor induces the downregulation of GLUT9, reabsorption urate transporter, together with the upregulation of ABCG2 and NPT1, secretion urate transporters, all changes of which clearly lead to increase in renal UA clearance. Hypouricemia seen in SIADH is attributable to V1a receptor stimulation.
Literature
1.
go back to reference Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1979;301(10):528–30.CrossRefPubMed Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med. 1979;301(10):528–30.CrossRefPubMed
2.
go back to reference Maesaka JK, Gupta S, Fishbane S. Cerebral salt-wasting syndrome: does it exist? Nephron. 1999;82(2):100–9.CrossRefPubMed Maesaka JK, Gupta S, Fishbane S. Cerebral salt-wasting syndrome: does it exist? Nephron. 1999;82(2):100–9.CrossRefPubMed
3.
go back to reference Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting? Kidney Int. 2009;76(9):934–8.CrossRefPubMed Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting? Kidney Int. 2009;76(9):934–8.CrossRefPubMed
4.
go back to reference Fenske W, Maier SK, Blechschmidt A, Allolio B, Stork S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am J Med. 2010;123(7):652–7.CrossRefPubMed Fenske W, Maier SK, Blechschmidt A, Allolio B, Stork S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am J Med. 2010;123(7):652–7.CrossRefPubMed
5.
go back to reference Dorhout Mees EJ, Blom van Assendelft P, Nieuwenhuis MG. Elevation of uric aicd clearance caused by inappropriate antidiuretic hormone secretion. Acta Med Scand. 1971;189(1–2):69–72.PubMed Dorhout Mees EJ, Blom van Assendelft P, Nieuwenhuis MG. Elevation of uric aicd clearance caused by inappropriate antidiuretic hormone secretion. Acta Med Scand. 1971;189(1–2):69–72.PubMed
6.
go back to reference Prospert F, Soupart A, Brimioulle S, Decaux G. Evidence of defective tubular reabsorption and normal secretion of uric acid in the syndrome of inappropriate secretion of antidiuretic hormone. Nephron. 1993;64(2):189–92.CrossRefPubMed Prospert F, Soupart A, Brimioulle S, Decaux G. Evidence of defective tubular reabsorption and normal secretion of uric acid in the syndrome of inappropriate secretion of antidiuretic hormone. Nephron. 1993;64(2):189–92.CrossRefPubMed
7.
go back to reference Decaux G, Namias B, Gulbis B, Soupart A. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996;7(5):805–10.PubMed Decaux G, Namias B, Gulbis B, Soupart A. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996;7(5):805–10.PubMed
8.
go back to reference Wright AF, Rudan I, Hastie ND, Campbell H. A ‘complexity’ of urate transporters. Kidney Int. 2010;78(5):446–52.CrossRefPubMed Wright AF, Rudan I, Hastie ND, Campbell H. A ‘complexity’ of urate transporters. Kidney Int. 2010;78(5):446–52.CrossRefPubMed
9.
go back to reference Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol. 2012;16(1):89–95.CrossRefPubMed Anzai N, Jutabha P, Amonpatumrat-Takahashi S, Sakurai H. Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol. 2012;16(1):89–95.CrossRefPubMed
10.
go back to reference Sakurai H. Urate transporters in the genomic era. Curr Opin Nephrol Hypertens. 2013;22(5):545–50.CrossRefPubMed Sakurai H. Urate transporters in the genomic era. Curr Opin Nephrol Hypertens. 2013;22(5):545–50.CrossRefPubMed
11.
go back to reference Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem. 2004;279(16):16229–36.CrossRefPubMed Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem. 2004;279(16):16229–36.CrossRefPubMed
12.
go back to reference Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Da Costa A, et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA. 2009;106(36):15501–6.CrossRefPubMedPubMedCentral Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Da Costa A, et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci USA. 2009;106(36):15501–6.CrossRefPubMedPubMedCentral
13.
go back to reference Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73(2):220–5.CrossRefPubMed Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73(2):220–5.CrossRefPubMed
14.
go back to reference Chiba T, Matsuo H, Kawamura Y, Nagamori S, Nishiyama T, Wei L, et al. NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout. Arthritis Rheumatol. 2015;67(1):281–7.CrossRefPubMed Chiba T, Matsuo H, Kawamura Y, Nagamori S, Nishiyama T, Wei L, et al. NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout. Arthritis Rheumatol. 2015;67(1):281–7.CrossRefPubMed
15.
go back to reference Yasuoka Y, Kobayashi M, Sato Y, Zhou M, Abe H, Okamoto H, et al. The intercalated cells of the mouse kidney OMCD(is) are the target of the vasopressin V1a receptor axis for urinary acidification. Clin Exp Nephrol. 2013;17(6):783–92.CrossRefPubMed Yasuoka Y, Kobayashi M, Sato Y, Zhou M, Abe H, Okamoto H, et al. The intercalated cells of the mouse kidney OMCD(is) are the target of the vasopressin V1a receptor axis for urinary acidification. Clin Exp Nephrol. 2013;17(6):783–92.CrossRefPubMed
16.
go back to reference Burnatowska-Hledin MA, Spielman WS. Vasopressin V1 receptors on the principal cells of the rabbit cortical collecting tubule. Stimulation of cytosolic free calcium and inositol phosphate production via coupling to a pertussis toxin substrate. J Clin Invest. 1989;83(1):84–9.CrossRefPubMedPubMedCentral Burnatowska-Hledin MA, Spielman WS. Vasopressin V1 receptors on the principal cells of the rabbit cortical collecting tubule. Stimulation of cytosolic free calcium and inositol phosphate production via coupling to a pertussis toxin substrate. J Clin Invest. 1989;83(1):84–9.CrossRefPubMedPubMedCentral
17.
18.
go back to reference Terada Y, Tomita K, Nonoguchi H, Yang T, Marumo F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest. 1993;92(5):2339–45.CrossRefPubMedPubMedCentral Terada Y, Tomita K, Nonoguchi H, Yang T, Marumo F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest. 1993;92(5):2339–45.CrossRefPubMedPubMedCentral
19.
go back to reference Tashima Y, Kohda Y, Nonoguchi H, Ikebe M, Machida K, Star RA, et al. Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats. Pflugers Arch. 2001;442(5):652–61.CrossRefPubMed Tashima Y, Kohda Y, Nonoguchi H, Ikebe M, Machida K, Star RA, et al. Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats. Pflugers Arch. 2001;442(5):652–61.CrossRefPubMed
20.
go back to reference Carmosino M, Brooks HL, Cai Q, Davis LS, Opalenik S, Hao C, et al. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol. 2007;292(1):F351–60.CrossRefPubMed Carmosino M, Brooks HL, Cai Q, Davis LS, Opalenik S, Hao C, et al. Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. Am J Physiol Renal Physiol. 2007;292(1):F351–60.CrossRefPubMed
21.
go back to reference Jung KY, Endou H. A novel vasopressin receptor in rat early proximal tubule. Biochem Biophys Res Commun. 1991;180(1):131–7.CrossRefPubMed Jung KY, Endou H. A novel vasopressin receptor in rat early proximal tubule. Biochem Biophys Res Commun. 1991;180(1):131–7.CrossRefPubMed
22.
go back to reference Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.CrossRefPubMed Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.CrossRefPubMed
23.
go back to reference Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.CrossRefPubMed Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.CrossRefPubMed
24.
go back to reference Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–64.CrossRefPubMed Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–64.CrossRefPubMed
25.
go back to reference Diamond H, Meisel A. Influence of volume expansion, serum sodium, and fractional excretion of sodium on urate excretion. Pflugers Arch. 1975;356(1):47–57.CrossRefPubMed Diamond H, Meisel A. Influence of volume expansion, serum sodium, and fractional excretion of sodium on urate excretion. Pflugers Arch. 1975;356(1):47–57.CrossRefPubMed
26.
go back to reference Maesaka JK. An expanded view of SIADH, hyponatremia and hypouricemia. Clin Nephrol. 1996;46(2):79–83.PubMed Maesaka JK. An expanded view of SIADH, hyponatremia and hypouricemia. Clin Nephrol. 1996;46(2):79–83.PubMed
27.
go back to reference Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404.CrossRefPubMedPubMedCentral Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404.CrossRefPubMedPubMedCentral
Metadata
Title
Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH
Authors
Kei Taniguchi
Yoshifuru Tamura
Takanori Kumagai
Shigeru Shibata
Shunya Uchida
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-016-1248-x

Other articles of this Issue 6/2016

Clinical and Experimental Nephrology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine